Clinical Trial Update: Cyclophosphamide as Graft-versus-host Prophylaxis After Allogeneic Stem Cell Transplantation for Multiple Myeloma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating cyclophosphamide as graft-versus-host disease prophylaxis after allogeneic stem cell transplantation in patients with multiple myeloma …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• CYCLOPHOSPHAMIDE (Cyclophosphamide)

Snippet

Sponsor: Universitätsklinikum Hamburg-Eppendorf | Conditions: Multiple Myeloma | Phase 2 | Status: COMPLETED